12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AMG 145: Phase II data

The double-blind, international Phase II GAUSS trial in 160 patients showed that all 3 doses of subcutaneous AMG 145 alone and AMG 145 plus ezetimibe met the primary endpoint of reducing LDL-C from baseline to week 12 vs. placebo plus ezetimibe. Specifically, AMG 145 alone given every 4 weeks led to mean reductions in LDL-C from baseline to week 12 of 41% in the 280 mg dose arm, 43% in the 350 mg dose arm and 51% in...

Read the full 369 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >